STANDARD OPERATING PROCEDURE
|
|
- Emma Hancock
- 6 years ago
- Views:
Transcription
1 STANDARD OPERATING PROCEDURE Title Reference Number End of Study Notification and Premature Discontinuation of a Study SOP-RES-025 Version Number 2 Issue Date 29 th Sep 2016 Effective Date 10 th Nov 2016 Review Date 10 th Nov 2018 Author(s) Reviewer(s) Teresa O Leary, Head of Regulatory Compliance Melanie Boulter, QA Auditor Authorisation (Original signatures are retained by Research & Innovation) Dr Stephen Ryder Director of Research & Innovation Dr Stephen Fowlie Medical Director 01 st Aug nd Sep 2016 USERS OF THIS STANDARD OPERATING PROCEDURE MUST REFER TO TO ENSURE THE MOST CURRENT VERSION IS BEING USED
2 Page 2 of 9 1. Document History Version Issue Date Reason for Change Number 1 3 rd March 2014 Original SOP. It replaces SOP th Sep 2016 Biennial review.
3 Page 3 of 9 2. Introduction At the end of a research study the relevant review bodies must be notified that the study has ended. This also applies if the study has halted temporarily or ended early. This standard operating procedure (SOP) describes the procedure for suspending or terminating a study, including premature discontinuation of a study. 3. Purpose and Scope This SOP applies to the procedures for performing suspension or termination activities for all clinical trials of investigational medicinal products (CTIMPs), non-ctimps or clinical investigations of medical devices (CMDs) where Nottingham University Hospitals NHS Trust (NUH) is acting as the Sponsor. It describes the steps to be followed by all staff at NUH and/or Third Party Service Providers (SP). This SOP does not apply to studies for which NUH is not the Sponsor. 4. Responsibilities CI/Study Team To inform Research and Innovation (R&I) of any closure, premature discontinuation or temporary suspension of a research study. To complete the relevant declaration form to provide R&I with adequate information to be able to report to the Research Ethics Committee (REC) and the Medicines and Healthcare products Regulatory Agency (MHRA) where appropriate. If stated in the protocol, the study team should prepare information to send out to participants to let them know that their participation in the study is now complete. Sponsor (R&I will fulfil Sponsor responsibilities on behalf of NUH) To inform the REC and MHRA of any closure, premature discontinuation or temporary suspension of a research study, this will be carried out by a Research Project Manager (RPM) or delegated member of the R&I team.
4 Page 4 of 9 5. Definitions CA CE CI CMD CTIMP Documas GCP HRA IMP MHRA NUH QA R&I REC RPM SOP SP TMF TSC Competent Authority (in the United Kingdom this is the MHRA) "Conformité Européene" which literally means "European Conformity". The CE mark is required for all new products which are subject to one or more of the European product safety Directives. It is a visible sign that the manufacturer of the product is declaring conformity with all of the Directives relating to that product Chief Investigator Clinical Investigation of a Medical Device Clinical Trial of an Investigational Medicinal Product A document management system to assist with the management, control and governance of the research and ethics processes covering research and development projects Good Clinical Practice Health Research Authority Investigational Medicinal Product Medicines and Healthcare products Regulatory Agency Nottingham University Hospitals NHS Trust Quality Assurance Research and Innovation Research Ethics Committee (in this SOP it refers to the committee providing the favourable opinion for the study) Research Project Manager Standard Operating Procedure Service Provider Trial Master File Trial Steering Committee 6. Procedure The definition of the end of study should be provided and justified in the protocol and any changes to this definition should be notified as a substantial amendment. In most cases the end of study will be the date of the last visit of the last participant or the completion of any follow-up monitoring and data collection described in the protocol. Final analysis of the data (following database lock) and report writing may occur after formal declaration of the end of the study.
5 Page 5 of 9 All end of study notifications will be stored in the study file; electronically, in the hard copy file and referenced in Documas. R&I will track end of study activities by completing the End of Study Notification Checklist (TAFR02501). Within one year from the end of the study the sponsor is required to produce the end of study report (for paediatric clinical trials please refer to the timelines set out in the European Commission Communication 2009/C28/01). It is the CI s responsibility to complete this (refer to SOP-RES-027 End of Study Report). 6.1 End of Study Notification for a CTIMP or a CMD The study team should inform R&I in writing (ResearchSponsor@nuh.nhs.uk) within three days of the end of the study. R&I will then be responsible for notifying the relevant bodies within the appropriate timelines that the study has ended. The CI should support R&I in completing the relevant documentation to be submitted Submitting the End of Study Notification for a CTIMP The R&I RPM will notify the REC and the MHRA when the trial has ended. This information will be sent when: i. The trial ends in the United Kingdom (UK) and/or ii. The complete trial has ended in all participating centres, in all countries within and outside the European Union (EU). The RPM must notify the REC and the CAs of the EU Member States concerned within 90 days of the end of trial as defined in the protocol. This notification will be sent using the EudraCT Declaration of the End of Trial Form. The RPM should inform the CI when the notification has been submitted. The CI should inform the funding body, TSC and any other relevant partners of the end of the trial. The RPM will contact the study team and CI to arrange a close out monitoring visit (refer to SOP-RES-026 Site Close Out) once the trial has ended.
6 Page 6 of Submitting the End of Study Notification for a CMD If the clinical investigation is of a non-ce marked device, or a CE marked device used outside of its intended purpose, the R&I RPM will notify the manufacturer immediately who should notify the MHRA that the clinical investigation has ended. The RPM will complete the Declaration of the End of a Study form (the HRA form used for all non- CTIMP studies) and submit it to the REC within 90 days of the end of the clinical investigation. If the clinical investigation uses a CE marked device within its intended purpose, and therefore does not fall under the scope of the MHRA, the RPM will complete the Declaration of the End of a Study form (the HRA form used for all non-ctimp studies) and submit it to the REC within 90 days of the end of the clinical investigation and inform the manufacturer (if appropriate) and the CI. The CI should inform the funding body, TSC and other partners as appropriate. 6.2 End of Study Notification for non-ctimp and non-cmd The CI must complete the Declaration of the End of a Study form and submit it to the REC within 90 days of the end of the study and provide a copy to the Sponsor (ResearchSponsor@nuh.nhs.uk). The CI should also notify the funding body, TSC and other partners as appropriate. 6.3 End of Study Notification for non NHS REC approved studies Where a project has HRA Approval and was not reviewed by an NHS REC, the HRA must be informed of when the study has ended. The RPM will notify the HRA by sending an to hra.approval@nhs.net with the IRAS ID and contact information (phone and ). 6.4 Early Termination of a Study The CI, R&I RPM or Head of Regulatory Compliance should discuss if the study requires early termination. Reasons for the early termination should be clearly explained and any follow up measures to be taken, if any (i.e. for safety reasons), should be described. R&I will be responsible for notifying the relevant bodies within the appropriate timelines that the study has ended. The CI should support R&I in completing the relevant documentation to be submitted.
7 Page 7 of Submitting the Early Termination Notification for a CTIMP Within 15 days of the termination the R&I RPM will notify the REC and the MHRA using the EudraCT Declaration of the End of Trial Form. The RPM should inform the CI when the notification has been submitted. The CI should inform the funding body, TSC and other partners as appropriate Submitting the Early Termination Notification for a CMD If the clinical investigation is of a non-ce marked device, or a CE marked device used outside of its intended purpose, the R&I RPM will notify the manufacturer immediately who should notify the MHRA that the clinical investigation has terminated early. The RPM will complete the Declaration of the End of a Study form and submit it to the REC within 15 days of the termination of the clinical investigation. If the clinical investigation uses a CE marked device within its intended purpose, and therefore does not fall under the scope of the MHRA, the RPM will complete the Declaration of the End of a Study form and submit it to the REC within 15 days of the end of the clinical investigation and inform the manufacturer (if appropriate). The CI should inform the funding body, TSC and other partners as appropriate. If the reason for early termination relates to significant non-compliance (e.g. by a SP or CI) the RPM will be instructed by the R&I Senior Research Manager or Head of Compliance to collect as much study information from the site(s) as possible. NUH QA may also be required to conduct and/or co-ordinate performance of a for cause audit to establish the extent of the problem and to provide support for NUH decisions. Studies which terminate early due to full recruitment being achieved do not need to be reported as terminating early. Early termination can be due to sponsor difficulties, amongst those could be issues of safety or slow recruitment. In all cases both the REC and CA must be notified Submitting the Early Termination Notification for non-ctimp and non-cmd Research
8 Page 8 of 9 The CI must complete the Declaration of the End of a Study form and submit it to the REC within 15 days of the termination of the study and provide a copy to the Sponsor (ResearchSponsor@nuh.nhs.uk). The CI should also notify the funding body, TSC and other partners as appropriate. 6.5 Temporary Suspension of a Study When any NUH-sponsored study is temporarily suspended, the R&I RPM will notify the MHRA (if a CTIMP or CMD) and the REC within 15 days of the temporary suspension taking effect. This includes unexpected difficulties not in keeping with the approved protocol. All sites taking part in the study should be informed of the temporary suspension and instructed that no further participants should be recruited to the study. The funding body, TSC and any other relevant partners should also be informed of the temporary suspension. This does not include studies where recruitment is suspended due to logistical reasons such as unavailability of the research team. The suspension notification should be made as a substantial amendment (refer to SOP- RES-024 Amendments) with the reasons for the temporary suspension clearly explained. Should a suspension of a site be determined to have been due to correctable errors following a QA audit and issuance of a Corrective Action Preventative Action request, it may be possible to remove the suspension after corrective actions have been applied by the affected site. To restart a trial that has been temporarily suspended, another substantial amendment should be submitted providing evidence that it is safe to restart the trial (refer to SOP-RES- 024 Amendments). If the Sponsor decides not to recommence the suspended study (i.e. to terminate the study), then the R&I RPM will ensure the REC and the CA are notified within 15 days of the decision to terminate the study (see 6.3). The information to be supplied on the end of trial notification form must include: i. Justification for premature termination of the trial; ii. Number of subjects involved; iii. Number of patients receiving any treatments; iv. Proposed management if patient treatments are involved;
9 Page 9 of 9 v. The consequences on the study data integrity and evaluation of results. 6.5 Trial Does not Commence For all NUH-sponsored studies if the CI or Sponsor decides not to commence the study, the CI should notify the MHRA (if a CTIMP or CMD) and REC clearly explaining the reasons for not starting the trial. 7. References and Associated Documents The Medicines for Human Use (Clinical Trials) Regulations 2004 The Medicines for Human Use (Clinical Trials) Amendment Regulations 2006 The Medical Devices Regulations 2002 The Medical Devices (Amendment) Regulations 2003 Medical Devices (Amendment) Regulations 2007 Medical Devices (Amendment) Regulations 2008 Research Governance Framework for Health and Social Care: Second edition, 2005 International Conference on Harmonisation Guidelines for Good Clinical Practice E6 (R1) ISO 14155:2011 Clinical investigation of medical devices for human subjects - Good clinical practice Good Clinical Practice Guide Compiled by the Medicines and Healthcare products Regulatory Agency, published 2012 SOP-RES-024 SOP-RES-026 SOP-RES-027 TAFR02501 Available from the HRA Website Amendments Site Close Out End of Study Report End of Study Notification Checklist Declaration of the End of Trial Form for CTIMP studies Declaration of the End of Study Form for non-ctimp studies
STANDARD OPERATING PROCEDURE
STANDARD OPERATING PROCEDURE Title Reference Number Training and Development SOP-QMS-007 Version Number 2 Issue Date 15 Apr 2016 Effective Date 26 May 2016 Review Date 26 May 2018 Author(s) Reviewer(s)
More informationSTANDARD OPERATING PROCEDURE
STANDARD OPERATING PROCEDURE Title Reference Number Archiving and the Destruction of Records SOP-RES-028 Version Number 2 Issue Date 08 th Dec 2015 Effective Date 22 nd January 2016 Review Date 22 nd January
More informationSTANDARD OPERATING PROCEDURE
STANDARD OPERATING PROCEDURE Title Reference Number Audits and Inspections SOP-QMS-004 Version Number 4 Issue Date 29 th Sep 2016 Effective Date 10 th Nov 2016 Review Date 10 th Nov 2018 Author(s) Reviewer(s)
More informationSTUDY CLOSURE AND ARCHIVING
STUDY CLOSURE AND ARCHIVING DOCUMENT NO.: CR009 v2.0 AUTHOR: Lynn Smith ISSUE DATE: 15 August 2016 EFFECTIVE DATE: 29 August 2016 1 INTRODUCTION 1.1 The Academic & Clinical Central Office for Research
More informationStandard Operating Procedure for Archiving
Standard Operating Procedure for Archiving SOP name: NWORTH07/19 archiving Version 2 Authorship Team: Angela Gliddon & Rhiannon Whitaker Meeting date reviewed 16 th April 2008 Designated NWORTH member
More informationMarie-Claire Good, RG and GCP Manager James Rickard, Deputy Chief Pharmacist Technical Services Cheryl Lawrence, Senior Research Pharmacist
Standard Operating Procedures (SOP) for: IMP Management BH/QMUL Sponsored CTIMPs SOP Number: 42a Version Number: 3.0 Effective Date: 14 th August 2017 Review Date: 14 th August 2019 Author: Reviewer: Reviewer:
More informationSTANDARD OPERATING PROCEDURE SOP 310
STANDARD OPERATING PROCEDURE SOP 310 DEVELOPMENT OF PARTICIPANT INFORMATION SHEET AND INFORMED CONSENT FORM Version 1.3 Version date 28.03.2017 Effective date 28.03.2017 Number of pages 8 Review date April
More informationSTANDARD OPERATING PROCEDURE SOP 320. Developing a Research Protocol
STANDARD OPERATING PROCEDURE SOP 320 Developing a Research Protocol Version 2.1 Version date 26.03.2017 Effective date 26.03.2017 Number of pages 14 Review date April 2019 Author NNUH UEA Joint Research
More informationDevelopment Safety Update Report Guidance
Development Safety Update Report Guidance This document provides instructions for the preparation and submission of a Development Safety Update Report (DSUR) for a Clinical Trial of an Investigational
More informationIMP Management and Accountability
This is a controlled document. The master document is posted on the JRCO website and any print-off of this document will be classed as uncontrolled. Researchers and their teams may print off this document
More informationTrial Master File / Investigator Site File Index Clinical Trials of Investigational Medicinal Products
1 Trial Master File / Investigator Site File Index Clinical Trials of Investigational Medicinal Products SECTION TITLE DOCUMENTS 1. Contact List Including details of relevant study site staff, responsible
More informationSponsorship of Clinical Research Studies
Sponsorship of Clinical Research Studies Category: Summary: Equality Impact Assessment undertaken: Policy The UK Policy Framework for Health and Social Care 2017 (UKPF) and The Medicines for Human Use
More informationStandard Operating Procedure: Obtaining Informed Consent from Competent Adults for Research Studies. SOP Number: UoA-NHSG-SOP-010 Version No: 2
Standard Operating Procedure: Obtaining Informed Consent from Competent Adults for Research Studies SOP Number: UoA-NHSG-SOP-010 Version No: 2 Author: Date: 27 th March 2015 (Carole Edwards, Lead Research
More informationMarie-Claire Rickard, RG and GCP Manager Cheryl Lawrence, Senior Research Pharmacist Damien Kelly, Barts Pharmacy Site and Clinical Trials Lead
Standard Operating Procedures (SOP) for: Pharmacy Involvement in Hosted Studies SOP Number: 42b Version Number: 2.0 Effective Date: 23 rd November 2015 Review Date: 2 nd November 2017 Author: Reviewer:
More informationTrial oversight SOP for HEY-sponsored CTIMPs
R&D Department Trial oversight SOP for HEY-sponsored CTIMPs Hull And East Yorkshire Hospitals NHS Trust 2010 All Rights Reserved No part of this document may be reproduced, stored in a retrieval system
More informationStudy Files and Filing
Study Files and Filing The current version of all Hillingdon Hospital R&D Guidance Documents and Standard Operating Procedures are available from the R&D Intranet and Internet sites: www.ths.nhs.uk/departments/research/research.htm
More informationCombined trial of an investigational medicinal product and an investigational medical device
Welcome to the Integrated Research Application System IRAS Project Filter The integrated dataset required for your project will be created from the answers you give to the following questions. The system
More informationRecording, Managing and Reporting Adverse Events in the UK
This is a controlled document. The master document is posted on the JRCO website and any print-off of this document will be classed as uncontrolled. Researchers and their teams may print off this document
More informationR&D Manager Hillingdon Hospital. Revision History Effective Date Reason For Change. recommendations Version no:
Research as a Participating site STANDARD OPERATING PROCEDURE FOR OVERSIGHT SOP No: P08/PF2 V2 Effective Date: 31 st July 2013 Supersedes: P08/PF2 Revision Date: 31 st March 2014 Author: Position: Approved
More informationGCP Basics - refresher
p. 01 GCP Basics - refresher Agenda: p. 02 Brief History of GCP GCP Regulations Principles of ICH E6 Sponsor Responsibilities Computer Systems Common Compliance Issues Brief History of GCP 3 Brief History
More informationStandard Operating Procedure (SOP) Research and Development Office
Standard Operating Procedure (SOP) Research and Development Office Title of SOP: Creation & Maintenance of an Investigator Brochure SOP Number: 34 Version Number: 1.0 Supercedes: N/A Effective date: August
More informationetmf A Regulators Perspective Paula Walker, GCP Operations Manager & Senior GCP Inspector
etmf A Regulators Perspective Paula Walker, GCP Operations Manager & Senior GCP Inspector Agenda EU Legislation and Guidance News/Updates relating to TMF Structure and Content of e/tmf Inspecting etmfs
More informationAuthor Signature: Date: 10 October 2017 The author is signing to confirm the technical content of this document
SOP Title: Investigator s Brochure Content, Design, Amendments, Filing & Distribution Author: Clinical Research and Development Office (CRDO) Author Signature: Date: 10 October 2017 The author is signing
More informationThis is a controlled document. The master document is posted on the JREO website and any print-off will be classed as uncontrolled.
Standard Operating Procedure (SOP) Investigator Preparation of Annual Developmental Safety and Update Report (DSUR) and its review and submission by the Sponsor SOP ID number: JREOSOP0008 Effective Date:
More informationGuide to Clinical Trial Applications
Guide to Clinical Trial Applications AUT-G0001-11 29 MAY 2018 This guide does not purport to be an interpretation of law and/or regulations and is for guidance purposes only. CONTENTS ABBREVIATIONS 3 1
More informationDate: 2 nd June 2010 Version: 3 Page 1 of 16 AND LABELLING (NWORTH 3.08) Principal Author Name: E. Bedson Signature: E. Bedson Date:15/06/10
Page 1 of 16 STANDARD OPERATING PROCEDURE FOR TRIAL SUPPLIES AND LABELLING (NWORTH 3.08) Approvals Principal Author Name: E. Bedson Signature: E. Bedson Date:15/06/10 Quality Assurance Officer Name: D.
More informationComparison of admission rates to neonatal units between PO screening and non-po screening Units
London - Westminster Research Ethics Committee 4 Minshull Street Manchester M1 3DZ Telephone: 0207 104 8012 Please note: This is the favourable opinion of the REC only and does not allow you to start your
More informationConfirming Research Study Capacity and Capability
Title: Outcome Statement: Written By: Confirming Research Study Capacity and Capability Researchers will be informed about the procedures and requirements for obtaining permission to conduct a research
More informationNEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES
NEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES SOP details SOP title: Trial Master File & Investigator Site File SOP number: TM 001 SOP category: Trial Management Version number: 03 Version
More informationRSC/CT Det. no. 1/2013
RSC/CT Det. no. 1/2013 Protocol 1631-P The English version of this Determination was prepared in order to help comprehension by non-italian mother tongue users, but is NOT an official document. Please
More informationInspections: an academic perspective
Inspections: an academic perspective Patricia Henley Quality and Governance Manager Head, Research Governance & Integrity Office London School of Hygiene & Tropical Medicine Email: patricia.henley@lshtm.ac.uk
More informationAPPLICANT'S CHECKLIST
APPLICANT'S CHECKLIST Research tissue bank (or other research biobank) REC Ref: Title of Tissue Bank: Applicant's Name: Name of Designated Individual: Please complete this checklist and send it with your
More informationSubmitting a CTA application to the MHRA
This is a controlled document. The master document is posted on the JRCO website and any print-off of this document will be classed as uncontrolled. Researchers and their teams may print off this document
More informationResearch Governance Policy
Research Governance Policy Version: Status: Title of originator/author: Name of responsible director: Developed/revised by group/committee and Date: Approved by group/committee and Date: Effective date
More informationImpact of the transposition of the European Clinical Trials Directive. CEMO, Paris 17 November 2004
Impact of the transposition of the European Clinical Trials Directive CEMO, Paris 17 November 2004 Dr Martine Dehlinger-Kremer VP Regulatory Affairs International Agenda Overview of key areas of Directive
More informationInvestigational Medicinal Product (IMP) Management Standard Operating Procedure
Reference Number: UHB 040 Version Number: 3 Date of Next Review: 26 Apr 2019 Previous Trust/LHB Reference Number: T 363 Standard Operating Procedure Introduction and Aim This procedure is written to support
More informationTrial Protocol. Version 1.2. Effective date: 18 May Dr Sarah Duggan, CTU Manager. V May 2010 Update web links.
Trial Version 1.2 Effective date: 18 May 2010 Reviewed by: Approved by: Claire Daffern, QA Manager Dr Sarah Duggan, CTU Manager Revision Chronology: Effective Date Reason for change V1.2 18 May 2010 Update
More informationQuality Assurance in Clinical Trials
Quality Assurance in Clinical Trials Doctor Catherine CORNU, Lyon clinical Investigation Centre EUDIPHARM December 5th, 2011 1 Introduction: quality in clinical research in human subjects Regulatory requirements:
More informationThe EFGCP Report on The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Ireland
The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Ireland Question 1: What laws or regulations apply to an application for conducting a clinical
More informationEU Portal and Database Update
EU Portal and Database Update TOPRA 4 October 2017 Presented by Noémie Manent on 4 October 2017 Committees and Inspections Department An agency of the European Union Table of content EMA Portal and Database
More informationEssential Healthcare Research Governance Processes. Cindy Cooper, Lindsay Unwin and Judith Cohen, UoS
Essential Healthcare Research Governance Processes Cindy Cooper, Lindsay Unwin and Judith Cohen, UoS Aims Overview of governance processes including recent changes to remit Reminder of HoD and PI responsibilities
More informationPERFORMANCE IN INITIATING AND DELIVERING CLINICAL RESEARCH INFORMATION SUBMISSION GUIDELINES
PERFORMANCE IN INITIATING AND DELIVERING CLINICAL RESEARCH INFORMATION SUBMISSION GUIDELINES Version Control Item 19 Items 25, 26 Item 29 Update to the Publication requirements Update of Submission Timetable
More informationComputer System Validation & Backup
REFERENCE: VERSION NUMBER: 1.1 EFFECTIVE DATE: 28-03-18 REVIEW DATE: 28-03-20 AUTHOR: Clinical Trials Manager, Clinical Trials Officer REVIEWED BY: R&I Senior Team APPROVED BY: Deputy Director of Research
More informationManagement and Accountability of Investigational Medicinal Products in the King s Clinical Research Facility
Management and Accountability of Investigational Medicinal Products in the King s Clinical Research Facility Document Detail Document type Standard Operating Procedure CRF-STU-SOP-1: Management and Accountability
More informationInspection of the conduct of clinical evaluations on medical devices in the premises of healthcare providers
ZP-21 Inspection of the conduct of clinical evaluations on medical devices in the premises of healthcare providers This guideline supersedes guideline SÚKL PZT-16 as of November 1, 2004. The purpose of
More informationHow to Apply for Ethics (Non-CTIMPs) including Sponsorship
How to Apply for Ethics (Non-CTIMPs) including Sponsorship Joint Research & Enterprise Office (JREO) St George s University of London Lucy H H Parker Clinical Research Governance Manager Joint Research
More informationScotland A REC 2 nd Floor Waverley Gate 2-4 Waterloo Place Edinburgh EH1 3EG
Scotland A REC 2 nd Floor Waverley Gate 2-4 Waterloo Place Edinburgh EH1 3EG Telephone: 0131-465-5679 19 February 2016 Professor Karim Brohi Professor of Trauma Science Queen Mary University of London
More informationANNEX. CHAPTER I General principles
ANNEX REGULATIONS on the authorisation by the NMA of clinical trials/notification to the National Medicines Agency of non-interventional studies on medicinal products for human use in Romania CHAPTER I
More informationECTU Central Office SOP ECTU_TM_17 Management of Trial (IMP) Supplies
ECTU Central Office SOP ECTU_TM_17 Management of Trial (IMP) Supplies SOP number: ECTU TM 17 Signature Date Authored by: Holly Ennis, Trial Manager 6 th Sept 2017 Reviewed by: Laura Forsyth, Trial Manager
More informationWorkstream 6: Pharmacovigilance
Workstream 6: Pharmacovigilance 1.0 Introduction... 2 1.1 Background... 2 1.2 Definitions... 3 2.0 Definition of Sponsor for Pharmacovigilance... 4 3.0 General Considerations: Risk Adapted Approaches to
More informationSupply of aseptically - prepared doses of IMPs across legal boundaries. Edition 1. December 2017
Supply of aseptically - prepared doses of IMPs across legal boundaries Edition 1 December 2017 Endorsed and supported by: NHS Pharmaceutical Quality Assurance Committee 2017 with National Pharmacy Clinical
More informationHospital Authority (HA) Guide on Research Ethics (for Study Site & Research Ethics Committee)
Page 1 of 8 Hospital Authority (HA) Guide on Research Ethics (for Study Site & Version Effective Date 2 01/02/2015 Document Number HAHO-CE&TM-HA REC Author HA Head Office Steering Committee on Research
More informationAudit Program Background Definition Management Example Content Risk assessment approach
AUDIT PROGRAM Audit Program Background Definition Management Example Content System audits vs study audits Risk assessment approach ICH-GCP E6 new content Management Example 2 Background - Definition There
More informationReflection paper on GCP compliance in relation to trial master files (paper and/or electronic) for management, audit and inspection of clinical trials
1 2 3 4 5 6 7 1 February 2013 EMA/INS/GCP/636736/2012 Good Clinical Practice Inspectors Working Group (GCP IWG) Reflection paper on GCP compliance in relation to trial master files (paper and/or electronic)
More informationAgenzia Italiana del Farmaco
Agenzia Italiana del Farmaco The Italian Legislation and the work of the Italian Medicines Agency (AIFA) in the field of ethics of Clinical Trials Umberto Filibeck AIFA Head of GCP Inspectorate and GCP
More informationMRC. Clinical Trials. Series MRC GUIDELINES FOR GOOD CLINICAL PRACTICE IN CLINICAL TRIALS. Medical Research Council
MRC Clinical Trials Series MRC GUIDELINES FOR GOOD CLINICAL PRACTICE IN CLINICAL TRIALS 1998 Medical Research Council MRC GUIDELINES FOR GOOD CLINICAL PRACTICE IN CLINICAL TRIALS 1998 MRC GUIDELINES FOR
More informationThe EFGCP Report on The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Bulgaria
The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Bulgaria Question 1: What laws or regulations apply to an application for conducting a clinical
More informationConducted Under an IND to Support a
Using Foreign Clinical Trial Data not Conducted Under an IND to Support a US Application PDA Midwest Chapter Meeting March 15, 2018 2013 2017 Regulatory Compliance Associates Inc. All Rights Reserved.
More informationRoles and responsibilities of members and alternates, rapporteur and peer reviewers, experts and observers of the Paediatric Committee (PDCO)
Last revision: 16 September 2010 EMA/537415/2008 Human Medicines Development and Evaluation Roles and responsibilities of members and alternates, rapporteur and peer reviewers, experts and observers of
More informationClinical Trials application process, legislation & guidelines
Clinical Trials application process, legislation & guidelines IMB Clinical Trials Seminar 19 th June 2012 Elaine Breslin MB BCh (NUI), PhD, FRCPI Clinical Assessment Manager 19/06/2012 Slide 1 IMB Mission
More informationNOTICE OF SUBSTANTIAL AMENDMENT
NOTICE OF SUBSTANTIAL AMENDMENT For use in the case of all research other than clinical trials of investigational medicinal products (CTIMPs). For substantial amendments to CTIMPs, please use the EU-approved
More informationEU Clinical Trial Regulation A view from the Industry
Conference EU Clinical Trial Regulation EU Clinical Trial Regulation A view from the Industry Judith Creba, Executive Director, EU Regulatory Strategy, Novartis Pharma AG University of Basel, Law Faculty
More informationPREPARING TO RUN A TRIAL
PREPARING TO RUN A TRIAL PHASE 1 STUDIES This phase is designed to assess the safety (pharmacovigilance), tolerability, pharmacokinetics, and pharmacodynamics of a drug. STUDY DESIGN Phase I clinical trials
More informationStandard Operating Procedure (SOP)
Standard Operating Procedure VALIDATION AND BACKUP OF COMPUTER SYSTEMS USED IN RESEARCH SETTING AUDIENCE ISSUE Trustwide Chief Investigators and associated Research Staff setting up and managing clinical
More informationEuropean Academy of Hospital Pharmacy Biotechnology Educational Summit. Clinical trials David Gerrett (Acknowledgment Mark Howells)
European Academy of Hospital Pharmacy Biotechnology Educational Summit Clinical trials David Gerrett (Acknowledgment Mark Howells) Objectives Have an appreciation and overview of clinical trials Understand
More information1 The Clinical Research Coordinator (CRC)... 1
TABLE OF CONTENTS Dedication... iii Introduction... xi 1 The Clinical Research Coordinator (CRC)... 1 Role and Responsibilities of the CRC...1 Personality and Skills... 3 Where Do CRCs Work?... 3 CRC Responsibilities...
More informationYour complimentary Clinica Medtech Intelligence content
Your complimentary Clinica Medtech Intelligence content Clinica provides you with up to the minute coverage and opinion on company, product, market and regulatory developments as well as market size, growth
More informationarena that impact on clinical development
RESEARCH DEVELOPMENT Changes in the regulatory arena that impact on clinical development 23 May 2011 Agenda Voluntary Harmonisation Procedure PIP and Paediatric requirements Changes to EudraCT and European
More informationINSPECTION OF INDEPENDENT ETHICS COMMITTEES (IEC) The Italian Experience
INSPECTION OF INDEPENDENT ETHICS COMMITTEES (IEC) The Italian Experience Umberto Filibeck Former Head of AIFA GCP Inspectorate and GCP Promotion Unit UNICRI Consultant for Projects on GCP of CTs in developing
More information3.1. Overall Principal Investigator (PI), who holds the IND and is the Sponsor.
SOP #: RCO-100 Page: 1 of 11 1. POLICY STATEMENT: An Overall Principal Investigator (PI) who holds an Investigational New Drug Application (IND) and who is the Sponsor of the research has additional responsibilities
More informationGuide for Manufacturers and Sponsors on Clinical Investigations Carried Out in Ireland
Guide for Manufacturers and Sponsors on Clinical Investigations Carried Out in Ireland AUT-G0095-1 15 AUGUST 2014 This guide does not purport to be an interpretation of law and/or regulations and is for
More informationThe New EU IVDR. Overview of the Main Changes & Clinical Data Requirements. Advance Regulatory Consulting Ltd.
Overview of the Main Changes & Clinical Data Requirements Advance Regulatory Consulting Ltd. : Timeline: Entry in to force Q2 (Apr) 2017 Adoption: +6m NB s apply for designation IVDs classified as Class
More informationGood Clinical Practice (GCP): how does a laboratory that supports a clinical trial ensure compliance with these Regulations
Good Clinical Practice (GCP): how does a laboratory that supports a clinical trial ensure compliance with these Regulations 9th edition of Synevo Clinical Research Symposium. 17 th November 2017 Bucharest.
More informationICH/GCP Guidelines Self-Evaluation Questionnaire
THE QUALITY ASSURANCE JOURNAL, VOL. 2, 74 82 (1997) ICH/GCP Guidelines Self-Evaluation Questionnaire The questionnaire below has been designed as a diverting, internal training tool by a group of employees
More informationMedical Device Directive
Medical Device Directive WG9 - IEC/SC 62A ISO/TC 184/SC 2 Joint Working Group 9 Saeed Zahedi 4 th of July 2012 Blatchford Copyright 2012 Commercial in confidence Definition and Requirements MDD is law,
More informationAn initial pilot assessment of the MHRA risk-adapted approaches to the management of clinical trials of investigational medicinal products
An initial pilot assessment of the MHRA risk-adapted approaches to the management of clinical trials of investigational medicinal products May 2011 1. Executive Summary 1.1. The NIHR Evaluation Trials
More information5 th Training Workshop for Micro-, Small- and Medium- Sized Enterprises (SMEs)
5 th Training Workshop for Micro-, Small- and Medium- Sized Enterprises (SMEs) GCP Requirements and Compliance Dr. Katalina Mettke BfArM, Germany Agenda Specialities of Early Development Trials Examples
More informationDeveloping a European First-in-Human Study: Three Key Decisions
Developing a European First-in-Human Study: Three Key Decisions By Nicole Feist, BA Clinical A key step in the translational medicine benchtop to bedside process model is the move from research and preclinical
More informationPlease note that these comments and the identity of the sender will be published unless a specific justified objection is received.
11.07.2017 Submission of comments on 'Guideline on GCP compliance in relation to trial master file (paper and/or electronic) for content, management, archiving, audit and inspection of clinical trials'
More informationQuality Site Visit Report FGK Clinical Research (FGK) GmbH, Munich Germany. Audit No. CT6018. Date of Audit: 3rd to 5th May 2017
Quality Site Visit Report FGK Clinical Research (FGK) GmbH, Munich Germany Head Office Address FGK Clinical Research GmbH Heimeranstrasse 35, 80339 Munich, Germany Research Centre Address FGK Clinical
More informationThe European Medicines Agency Inspections ANNEX IV TO PROCEDURE FOR CONDUCTING GCP INSPECTIONS REQUESTED BY THE EMEA:
The European Medicines Agency Inspections London, 20 September 2007 EMEA/INS/GCP/197221/2005 Procedure no.: INS/GCP/3/IV ANNEX IV TO PROCEDURE FOR CONDUCTING GCP INSPECTIONS REQUESTED BY THE EMEA: SPONSOR
More information1.4 Applicable Regulatory Requirement(s) Any law(s) and regulation(s) addressing the conduct of clinical trials of investigational products.
1.1 Adverse Drug Reaction (ADR) In the pre-approval clinical experience with a new medicinal product or its new usages, particularly as the therapeutic dose(s) may not be established: all noxious and unintended
More informationMEDICAL DEVICE CLINICAL INVESTIGATIONS AND ISO 14155
MEDICAL DEVICE CLINICAL INVESTIGATIONS AND ISO 14155 EXECUTIVE SUMMARY Medical device regulations around the world generally require manufacturers of most types of medical devices to supply data as part
More informationEuropean Commission: Assessment Of The Functioning Of The Clinical Trials Directive 2001/20/EC. MRC Response to Public consultation on EUCTD
European Commission: Assessment Of The Functioning Of The Clinical Trials Directive 2001/20/EC MRC Response to Public consultation on EUCTD January 8 th 2010 Introduction The Medical Research Council (MRC)
More informationPrecision-Panc Master Protocol: Personalising treatment for pancreatic cancer.
Precision-Panc Master Protocol: Personalising treatment for pancreatic cancer. Initiation Slides (Version 1 Draft 2 : 30 th October 2017) Sponsor: NHS Greater Glasgow and Clyde Chief Investigators: Dr
More informationQuality Assurance of Investigational Medicinal Products. Sue McKenzie PPQA (A)
Quality Assurance of Investigational Medicinal Products Sue McKenzie PPQA (A) Agenda for Today IMP Regulations - CTD and Annex 13 Role of QP for IMP Challenges of IMP Manufacture for the QP IMP Regulations
More informationGUIDELINES ON MEDICAL DEVICES GUIDE FOR COMPETENT AUTHORITIES IN MAKING AN ASSESSMENT OF CLINICAL INVESTIGATION NOTIFICATION
EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Cosmetics and Medical Devices MEDDEV 2.7.2 December 2008 GUIDELINES ON MEDICAL DEVICES GUIDE FOR COMPETENT AUTHORITIES IN
More informationDraft proposal for an addendum, on transparency, to the Functional specifications for the EU portal and EU database to be audited - EMA/42176/2014
20 January 2015 EMA/641479/2014 Compliance and Inspections Draft proposal for an addendum, on transparency, to the Functional specifications for the EU portal and EU database to be audited - EMA/42176/2014
More informationRISK MANAGEMENT COMMITTEE TERMS OF REFERENCE
RISK MANAGEMENT COMMITTEE TERMS OF REFERENCE Terms of Reference Agreed by the Committee Signed by the Chair on Behalf of the Committee Print Signature Date 16 th December 2011 Review Date December 2012
More informationClinical Trial Transparency UK perspective
Clinical Trial Transparency UK perspective Dr Bina Rawal Medical, Innovation & Research Director Association of the British Pharmaceutical Industry January 2014 1 Outline Transparency timeline Campaign
More informationInstruction document of the Spanish Agency of Medicines and Medical Devices for conducting clinical trials in Spain
DEPARTMENT OF MEDICINAL PRODUCTS FOR HUMAN USE Instruction document of the and Medical Devices for conducting clinical trials in Spain Version 9 dated 22 nd February 2018 Date of publication: 24 April
More informationResearch Governance Policy and Procedure
Research Governance Policy and Procedure Version: 5 Name of originator/author: Name of executive lead: Date ratified: Review date: APPLICABLE TO: All staff. EXECUTIVE SUMMARY Dr Lisa Austin- University
More informationClinical Trial Safety Reporting requirements
Clinical Trial Safety Reporting requirements SME info day 20 Mar 2017 Presented by Sophia Mylona Clinical & Non-clinical Compliance, European Medicines Agency An agency of the European Union Article Regulation
More informationCOMPUTER SYSTEMS VALIDATION
COMPUTER SYSTEMS VALIDATION DOCUMENT NO.: POL007 v1.0 AUTHOR: Lorn Mackenzie ISSUE DATE: 04 AUG 2017 1 INTRODUCTION 1.1 The Academic & Clinical Central Office for Research & Development (ACCORD) is a joint
More informationMedical Literature Monitoring
Medical Literature Monitoring 5 th Industry Platform on the implementation of EU pharmacovigilance legislation Presented by Tom Paternoster-Howe on 15 September 2015 EMA/Information Management/Data Standardisation
More informationQUESTIONNAIRE FOR COMPETENT AUTHORITIES TO BE USED FOR ASSESSMENT, REASSESSMENT AND SELF- EVALUATION
PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME PS/W 1/2011 2 Annexes 22 July 2011 QUESTIONNAIRE FOR COMPETENT AUTHORITIES TO BE USED FOR ASSESSMENT, REASSESSMENT AND SELF- EVALUATION PIC/S 2011 Reproduction
More informationStandard Operating Procedure
SOP number: Standard Operating Procedure SOP-JRO-015-001 SOP full title: Consent and Sample Tracking for Samples Collected for the Newcastle Biomedicine Research Tissue Bank (REC no. 12/NE/0395) SOP effective:
More informationGood Clinical Practice
Dublin Academic Medical Centre Good Clinical Practice Patrick Murray, MD, FASN, FRCPI Professor, University College Dublin, Mater Misericordiae University Hospital, Dublin, Ireland patrick.murray@ucd.ie
More informationFergus Sweeney, European Medicines Agency
Fergus Sweeney, European Medicines Agency Disclaimer The views presented in this presentation/these slides are those of the author and should not be understood or quoted as being made on behalf of the
More information